Davunetide
Also referenced as: NAP, AL-108
An ADNP-derived octapeptide investigated for neuroprotection.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Not FDA Approved
Not FDA-approved. Clinical investigation is not an approval for dementia, cognitive enhancement or neuroprotection.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An ADNP-derived octapeptide investigated for neuroprotection.
Not FDA-approved. Clinical investigation is not an approval for dementia, cognitive enhancement or neuroprotection.
Negative clinical results must be weighed more heavily than favorable laboratory neuroprotection claims.
Why It's Being Studied
- Progressive supranuclear palsy
- Microtubule biology
Mechanism of Action
Proposed activity concerns microtubule-associated cellular protection; a plausible mechanism has not translated into demonstrated benefit in its pivotal trial.
Proposed activity concerns microtubule-associated cellular protection; a plausible mechanism has not translated into demonstrated benefit in its pivotal trial. Negative clinical results must be weighed more heavily than favorable laboratory neuroprotection claims.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Progressive supranuclear palsy
- Microtubule biology
- Intranasal clinical research
Evidence Summary
A randomized phase 2/3 progressive supranuclear palsy trial did not improve the primary clinical outcomes.
Higher tiers carry more weight. Filled tiers have evidence for Davunetide; tap to read it.
- A randomized phase 2/3 progressive supranuclear palsy trial did not improve the primary clinical outcomes.
1 cited sources.
- Randomised controlled trial1
Human clinical evidence
- A randomized phase 2/3 progressive supranuclear palsy trial did not improve the primary clinical outcomes.
Reported Adverse Events in Research
- Trial tolerability does not establish long-term safety for unrelated uses; nasal effects depend on formulation.
Limitations of Current Evidence
- Negative clinical results must be weighed more heavily than favorable laboratory neuroprotection claims.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Davunetide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Not FDA Approved | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intranasal clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Randomised controlled trial
Davunetide — randomised controlled trial